Atopy and Frequency of Exacerbation in Chronic Obstructive Pulmonary Disease Patients

Launched by MANSOURA UNIVERSITY HOSPITAL · Jul 23, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how having allergies (atopy) affects the frequency of flare-ups or worsening symptoms in patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a long-term lung condition that makes it hard to breathe and can cause symptoms like coughing, mucus production, and shortness of breath. The study aims to understand if allergies play a role in how often these symptoms get worse.

To participate in this trial, you need to be an adult between the ages of 40 and 70 who has been diagnosed with COPD according to specific guidelines. However, if you have any known allergic conditions, other serious lung diseases, or significant health issues that could affect your breathing, you may not be eligible. If you qualify and choose to take part, you can expect to undergo assessments related to your COPD and possibly contribute to important research that could help improve understanding and treatment of this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria
• Exclusion Criteria:
• • Patients with known allergic diseases before enrollment
• • Patients with associated other chronic respiratory disorders
• • Patients with significant comorbidities that could influence respiratory function.
• • Recent respiratory infections or use of systemic corticosteroids within the last month before enrollment.